Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

200.48 +0.07 (+0.03%)
Streaming Delayed Price Updated: 10:02 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! Rub that sleep out our your eyes because we're going over the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Why Are Seagen Shares Sinking Today?
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shar... 
Via Benzinga
Recap: Seagen Q4 Earnings
Seagen (NASDAQ:SGEN) reported its Q4 earnings results on Wednesday, February 9, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Seagen missed estimated earnings by... 
Via Benzinga
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
Where Seagen Stands With Analysts
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analy... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
Seagen Publishes Inaugural Corporate Responsibility Report
SOURCE: Seagen 
Via 3BL Media
Topics Emissions
Exposures Product Safety
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
From Seagen Inc.
Via Business Wire
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Seagen Inc.
Via Business Wire
A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls Over 1%
Pre-open movers 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
From Seagen Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
Will Chart Analysts Notice Bad Omen on Seagen's Chart
If history is any guide, there may be trouble ahead for shares of Seagen (NASDAQ:SGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer
Seagen Inc (NASDAQ: SGEN) announced data from a Phase 1 trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic pancreatic ductal... 
Via Benzinga
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
From Seagen Inc.
Via Business Wire
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients
Seagen Inc (NASDAQ: SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab &... 
Via Benzinga
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
From Seagen Inc.
Via Business Wire
Why This Investor Is Selling His Seagen Shares
Having fallen more than 22% over the last month, Seagen Inc (NASDAQ: SGEN) shares are now trading down about 15% year-to-date. With Seagen stock seemingly stuck in a downtrend,... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Investing $100,000 Into These 2 Stocks 10 Years Ago Would Have Made You a Millionaire Today
And doing so wouldn't have involved gambling with your portfolio, either. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.